PMID: 7159690Oct 1, 1982Paper

Bioavailability of bemetizide and triamterene from a combination formulation

Biopharmaceutics & Drug Disposition
R R BrodieL M Walmsley


The bioavailability of the thiazide diuretic bemetizide from a tablet containing 25 mg of this drug and 50 mg of the chemically unrelated diuretic triamterene was lower than, and significantly different (p less than 0.01) from that from a tablet containing 25 mg bemetizide alone. The mean peak plasma level of bemetizide after administration of the combination tablet (68.3 ng ml-1) was lower than that after administration of bemetizide alone (87.9 ng ml-1), although the times of occurrence of the peak levels were similar. The bioavailability of triamterene from the combination tablet was greater than, but not significantly different from that after administration of a capsule containing 50 mg triamterene alone. The mean peak plasma level of triamterene after administration of the combination tablet (44.6 ng ml-1) was higher than and significantly different (p less than 0.001) from that after administration of triamterene alone (15.7 ng ml-1). Although bemetizide is unstable in urine, measurement of the apparent excretion of unchanged drug in the 24 h post-dose urine (less than 4 per cent of the dose) agreed with the estimate of drug bioavailability from the plasma level data. Less than 2 per cent of the dose of triamterene was e...Continue Reading


Aug 1, 1979·European Journal of Clinical Pharmacology·U Gundert-RemyE Mutschler
Mar 1, 1979·Journal of Chromatography·S SvedI J McGilveray
Dec 2, 1977·European Journal of Clinical Pharmacology·B Beermann, M Groschinsky-Grind
Feb 1, 1978·Clinical Pharmacology and Therapeutics·D C Hobbs, T M Twomey
May 17, 1978·European Journal of Clinical Pharmacology·B BeermannB Wikland
Jan 1, 1977·Journal of Clinical Pharmacology·G J YakatanJ T Doluisio
May 1, 1977·Clinical Pharmacology and Therapeutics·A W PruittP G Dayton
Oct 1, 1977·Clinical Pharmacology and Therapeutics·B BeermannB Lindström
Sep 1, 1968·Clinical Pharmacology and Therapeutics·P J TannenbaumA P Crosley
Jan 1, 1963·Acta Pharmacologica Et Toxicologica·J B LASSEN, O E NIELSEN


Dec 16, 2000·Drug Metabolism and Drug Interactions·S S JacobW D Hooper
Nov 1, 1986·Biopharmaceutics & Drug Disposition·P G Welling

Related Concepts

Chloride Ion Level
Diuretic Effect
Drug Combinations
Sodium Chloride Symporter Inhibitors

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Lipidomics & Rhinovirus Infection

Lipidomics can be used to examine the lipid species involved with pathogenic conditions, such as viral associated inflammation. Discovered the latest research on Lipidomics & Rhinovirus Infection.

Spatio-Temporal Regulation of DNA Repair

DNA repair is a complex process regulated by several different classes of enzymes, including ligases, endonucleases, and polymerases. This feed focuses on the spatial and temporal regulation that accompanies DNA damage signaling and repair enzymes and processes.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Torsion Dystonia

Torsion dystonia is a movement disorder characterized by loss of control of voluntary movements appearing as sustained muscle contractions and/or abnormal postures. Here is the latest research.

Archaeal RNA Polymerase

Archaeal RNA polymerases are most similar to eukaryotic RNA polymerase II but require the support of only two archaeal general transcription factors, TBP (TATA-box binding protein) and TFB (archaeal homologue of the eukaryotic general transcription factor TFIIB) to initiate basal transcription. Here is the latest research on archaeal RNA polymerases.

Alzheimer's Disease: MS4A

Variants within the membrane-spanning 4-domains subfamily A (MS4A) gene cluster have recently been implicated in Alzheimer's disease in genome-wide association studies. Here is the latest research on Alzheimer's disease and MS4A.

Central Pontine Myelinolysis

Central Pontine Myelinolysis is a neurologic disorder caused most frequently by rapid correction of hyponatremia and is characterized by demyelination that affects the central portion of the base of the pons. Here is the latest research on this disease.